Calcification of multipotent prostate tumor endothelium (Cancer Cell, 2008, 14:201-211)

報告日期: 2008/11/21
報告時間: 17:10/18:00
報告學生: 黃晟協
講評老師: 賴明德
附件下載:

http://basicmed.med.ncku.edu.tw/admin/up_img/971121-3.pdf

Calcification of multipotent prostate tumor endothelium

Andrew C. Dudley, Zia A. Khan, Shou-Ching Shin, Soo-Young Kang, Bernadette M. M. Zwaans,
Joyce Bischoff, and Michael Klagsbrun

Cancer cell, Vol. 14, 201-211, 2008

 

Speaker: Cheng-Hsieh Huang

Commentator: Lai, Ming-Derg

Date 2008/11/21 17:10-18:00

Place: Room 602

 

Abstract:

Angiogenesis is defined as the new blood vessels formation, which supports tumor growth and facilitates metastasis. Most new blood vessels arise by co-option or spouting of pre-existing endothelial cells (ECs). Endothelial cells in cancer cells have been frequently found in tumor, and which are called tumor endothelial cells (TECs).  The biological functions and the difference between TECs and ECs are still unclear. In this study, the authors isolated TECs from TRAMP mice. These TECs expressed the markers of hematopoietic and mesenchymal stem cells and were able to differentiate into cartilage- and bone-like tissues. Moreover, TECs incubated at selected medium would undergo osteogenic differentiation. The chrondrogenic differentiation was accompanied by up-regulation of cartilage-specific col2a1 and sox9 genes. In human and mice prostate tumors, ectopic vascular calcification occurred predominately in the lumen and colocalized with the endothelial marker CD31. This indicated that, prostate tumor endothelial cells were atypically multipotent and could undergo a mesenchymal-like transition. Calcification of tumor endothelial cells would lead to loss of barrier function of normal blood vessels and enable tumor cells to intravaste into blood stream. Moreover, vascular calcification in tumors is easily discernible by the standard histological techniques and may be useful as a diagnostic tool.

 

References:

1.   Understanding tumor endothelial cell abnormalities to develop ideal anti-angiogenic therapies. Cancer Sci. 99: 459-466, 2008.

2.   Growth factors for bone growth and repair: IGF, TGFb and BMP. Bone 19:  1S-12S, 1996.

3.   Multilineage potential of adult human mesenchymal stem cells. Science. 284: 143-147, 1999.

4.   Tumor endothelial cells express epidermal growth factor receptor (EGFR) but not ErbB3 and are responsive to EGF and to EGFR kinase inhibitors. Cancer Res. 66: 2173-2180, 2006.